NO20042779L - Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger - Google Patents

Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger

Info

Publication number
NO20042779L
NO20042779L NO20042779A NO20042779A NO20042779L NO 20042779 L NO20042779 L NO 20042779L NO 20042779 A NO20042779 A NO 20042779A NO 20042779 A NO20042779 A NO 20042779A NO 20042779 L NO20042779 L NO 20042779L
Authority
NO
Norway
Prior art keywords
agonist
partial
pharmaceutical compositions
containing pharmaceutical
compositions
Prior art date
Application number
NO20042779A
Other languages
English (en)
Norwegian (no)
Inventor
Jerome Aubert
Vitzing Christian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20042779L publication Critical patent/NO20042779L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20042779A 2001-12-21 2004-07-01 Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger NO20042779L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20042779L true NO20042779L (no) 2004-09-17

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042779A NO20042779L (no) 2001-12-21 2004-07-01 Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger

Country Status (31)

Country Link
US (2) US20050106236A1 (enExample)
EP (2) EP1321142A1 (enExample)
JP (1) JP4718776B2 (enExample)
KR (1) KR100980144B1 (enExample)
CN (1) CN100464749C (enExample)
AR (1) AR037937A1 (enExample)
AT (1) ATE320807T1 (enExample)
AU (1) AU2002361198B2 (enExample)
BR (1) BR0215148A (enExample)
CA (1) CA2470668C (enExample)
CO (1) CO5640102A2 (enExample)
CY (1) CY1105559T1 (enExample)
DE (1) DE60210139T2 (enExample)
DK (1) DK1458377T3 (enExample)
EC (1) ECSP105163A (enExample)
EG (1) EG24194A (enExample)
ES (1) ES2258171T3 (enExample)
HU (1) HU226589B1 (enExample)
IL (2) IL162451A0 (enExample)
MX (1) MXPA04006157A (enExample)
MY (1) MY139546A (enExample)
NO (1) NO20042779L (enExample)
NZ (1) NZ533585A (enExample)
PE (1) PE20030872A1 (enExample)
PL (1) PL369509A1 (enExample)
PT (1) PT1458377E (enExample)
RU (1) RU2322978C2 (enExample)
SI (1) SI1458377T1 (enExample)
TW (1) TWI260221B (enExample)
WO (1) WO2003053432A1 (enExample)
ZA (1) ZA200404467B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID28510A (id) * 1998-08-21 2001-05-31 Novartis Ag Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
BR122018074353B8 (pt) 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
US20070065801A1 (en) * 2003-05-21 2007-03-22 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4)
PE20050253A1 (es) * 2003-07-24 2005-06-03 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
AR045637A1 (es) 2003-09-12 2005-11-02 Amgen Inc Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio
EP1594493A2 (en) * 2003-12-16 2005-11-16 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103819403B (zh) 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
RU2015107019A (ru) 2012-08-21 2016-10-10 Эрделикс Инк. Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105392483B (zh) 2013-04-12 2019-03-15 阿德利克斯公司 用于抑制磷酸盐转运的nhe3结合化合物和方法
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
KR20240090875A (ko) 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd 1−アザビシクロ[3.3.0]オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
ID28510A (id) * 1998-08-21 2001-05-31 Novartis Ag Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ATE399554T1 (de) * 1999-08-03 2008-07-15 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil

Also Published As

Publication number Publication date
EP1321142A1 (en) 2003-06-25
RU2322978C2 (ru) 2008-04-27
DE60210139D1 (de) 2006-05-11
EP1458377B1 (en) 2006-03-22
NZ533585A (en) 2006-04-28
HU226589B1 (en) 2009-04-28
PL369509A1 (en) 2005-04-18
BR0215148A (pt) 2004-10-19
ES2258171T3 (es) 2006-08-16
IL162451A (en) 2009-02-11
HUP0402492A3 (en) 2008-04-28
US20050106236A1 (en) 2005-05-19
ZA200404467B (en) 2006-05-31
CY1105559T1 (el) 2010-07-28
ATE320807T1 (de) 2006-04-15
TW200410684A (en) 2004-07-01
DK1458377T3 (da) 2006-06-12
MXPA04006157A (es) 2004-10-27
KR100980144B1 (ko) 2010-09-03
AU2002361198B2 (en) 2006-06-08
KR20040066922A (ko) 2004-07-27
JP2005516946A (ja) 2005-06-09
EG24194A (en) 2008-10-14
WO2003053432A1 (en) 2003-07-03
TWI260221B (en) 2006-08-21
RU2004122631A (ru) 2005-08-10
PE20030872A1 (es) 2003-11-24
MY139546A (en) 2009-10-30
PT1458377E (pt) 2006-07-31
US20090104263A1 (en) 2009-04-23
JP4718776B2 (ja) 2011-07-06
ECSP105163A (es) 2010-07-30
CO5640102A2 (es) 2006-05-31
IL162451A0 (en) 2005-11-20
CA2470668C (en) 2011-07-05
CN100464749C (zh) 2009-03-04
SI1458377T1 (sl) 2006-08-31
CA2470668A1 (en) 2003-07-03
CN1606438A (zh) 2005-04-13
AR037937A1 (es) 2004-12-22
DE60210139T2 (de) 2006-08-17
HUP0402492A2 (hu) 2005-07-28
EP1458377A1 (en) 2004-09-22
AU2002361198A1 (en) 2003-07-09

Similar Documents

Publication Publication Date Title
FI20011478A0 (fi) Farmaseuttinen koostumus
FI20010780A0 (fi) Parannetut koostumukset
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
EE200300416A (et) Ravimvorm
ITMI20010748A0 (it) Composizioni farmaceutiche
GB0111597D0 (en) Pharmaceutical compositions
NO20052306D0 (no) Dispergerbare farmasoytiske blandinger.
IL162451A0 (en) 5Ht4 partial agonist pharmaceutical compositions
BR0210619A (pt) composição
IS7051A (is) Lyfjasamsetningar
IS7081A (is) Lyfjablanda
FI20022128A7 (fi) Farmaseuttinen koostumus
NO20026123L (no) Farmasöytiske sammensetninger
EP1461096A4 (en) ROTATING COMPRESSOR
NO20031095D0 (no) Farmasöytiske sammensetninger
GB0104752D0 (en) Pharmaceutical compositions
ITTO20020744A0 (it) Composizione
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
DE60140529D1 (de) Feuerlöschende Zusammensetzung
ITTO20020745A0 (it) Composizione
EE200200689A (et) Ravimkoostised
NO20015694D0 (no) Emballasje

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application